Aveo said in January it would end a mid-stage trial
testing the drug, Tivozanib, as a treatment for breast cancer due to
The drug has already been rejected as a treatment for kidney cancer
in June because of inconsistent study results.
The termination of the collaboration will be effective August 11,
after which the drug's rights will be returned to Aveo, the
companies said on Friday.
(Reporting by Natalie Grover in
Bangalore; editing by Savio D'Souza)
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.